Professor David Meiri, PhD, is Associate Professor at the Faculty of Biology at the Technion and a member of the Technion Integrated Cancer Center (TICC). Professor Meiri holds a M.Sc. in Biochemistry and a Ph.D. in plant biotechnology from Tel Aviv University. He conducted his post-doctoral fellowship at the Ontario Cancer Institute where he focused on tumour invasion and metastasis.
During his post-doctoral studies, he expanded his knowledge in human biology and cancer pathogenesis and gained worldwide recognition as an expert in the fields of G-protein coupled receptors (GPCRs), small GTPases and cytoskeleton. Upon completion of his post-doctoral fellowship, Professor Meiri took a position at the Technion Israel Institute of Technology, where he heads the “Laboratory of Cancer Biology and Cannabinoid Research”.
Presently, his lab investigates the therapeutic potential of phytocannabinoids, with focus on the antitumor effects of cannabinoids.
In addition to the laboratory cannabis research performed on-site, Professor Meiri collaborates with cannabis growers, clinicians, major manufacturers and distributors of medical cannabis for the purpose of revolutionising cannabis treatments.
Dr Mark Smith is an experienced UK-trained GP with interests in chronic disease management, sports injuries and diving, and aviation medicals. In 2015 looking for a career change and a new challenge, he moved with his wife who is also a GP to Perth in Australia.
Mark was one of the first GPs in Austra lia to prescribe medical cannabis to his patients and began prescribing shortly after legislation change in 2019.
Here he talks about his journey and personal experiences of prescribing and how this has changed his practice and approach to his wider clinical care. He is also uniquely placed to be able to compare and contrast the different approaches taken by Australia and the UK towards access to medical cannabis and the wider role of GPs in prescribing.